New reporting describes how automation and AI are changing organoid research workflows, enabling teams to move beyond traditional 2D cell culture and animal models. The article frames organoids as a more physiologically relevant platform and points to toolchains that accelerate preclinical testing and decision-making. The emphasis is on operational speed—using automated handling and analytics to scale experiments—while AI supports interpretation of complex biological readouts. In drug discovery, such upgrades can reduce cycle times from assay design to results. For biotech R&D leaders, the story highlights why organoid-based screening is increasingly paired with industrialized data pipelines rather than remaining a largely bespoke research approach.